Archives

International Journal of Pure & Applied Bioscience (IJPAB)
Year : 2018, Volume : 6, Issue : 4
First page : (683) Last page : (687)
Article doi: : http://dx.doi.org/10.18782/2320-6846

Immunogenicity and Safety Study on Rabivac Vet, Rabies Veterinary Vaccine, Inactivated (Cell Culture) in Dogs

Patil S.S.*, Aher V.D., Sunil N.S.*, Deshmukh V.V.**, Reddy G.S.*. and Rao T.V.S.*

College of Veterinary & Animal Sciences, MAFSU, Parbhani-431 402
*Corresponding Author E-mail: vivekdes@gmail.com
Received: 21.07.2018  |  Revised: 16.08.2018   |  Accepted: 26.08.2018  

 

 ABSTRACT

The present study was planned to study immunogenicity and safety of Rabivac Vet, an anti-rabies veterinary vaccine containing BHK-21 cell culture adapted rabies virus strain PV11 and inactivated with binary ethylenimine (BEI). A total of 100 dogs were divided into 3 groups, Group ‘A’ (24), Group ‘B’ (58) and Group ‘C’ (18). Rapid Fluorescent Focus Inhibition Test (RFFIT) was used for estimation of rabies virus neutralizing antibodies in pre and post vaccinated serum samples. In groups A, B and C the geometric mean antibody titre (RFFIT) values on the day of vaccination were 0.09 IU/ml, 1.51 IU/ml and 0.08 IU/ml respectively. There was a marked increase in geometric mean RFFIT values above protective level prescribed by WHO in all the groups at 28-30 days post vaccination. The RFFIT values of groups A, B and C on 28-30 days post vaccination were 3.22, 11.46 and 3.81 IU/ml respectively. The vaccine was found to be safe and efficacious in dogs against rabies.

Key words: BHK-21, PV11, Binary ethylenimine, Rapid Fluorescent Focus Inhibition Test, Rabivac Vet

Full Text : PDF; Journal doi : http://dx.doi.org/10.18782

Cite this article: Patil, S.S., Aher, V.D., Sunil, N.S., Deshmukh, V.V., Reddy, G.S. and Rao, T.V.S., Immunogenicity and Safety Study on Rabivac Vet, Rabies Veterinary Vaccine, Inactivated (Cell Culture) in Dogs, Int. J. Pure App. Biosci.6(4): 683-687 (2018). doi: http://dx.doi.org/10.18782/2320-7051.6846